(AOF) – Mauna Kea Technologies announces that, as part of its collaboration with Johnson & Johnson’s Lung Cancer Initiative (LCI), initial patient recruitment has begun in a prospective, multicenter, open-label, one-time clinical feasibility study. single arm, sponsored by the LCI. “The study will validate Cellvizio as a real-time biopsy guidance tool during robotic bronchoscopic navigation that may reduce the rate of non-contributing transbronchial biopsies of peripheral lung cancer” , explains the company.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.